EPCAM and neoplasm: Immunofluorescence analysis of tumor volumes did not reveal differences between mice treated with EpCAM/GFPCAR T-cell and concurrent aPD-1 treatment and those given EpCAM/GFPCAR T-cell with the isotype control antibody (40 mm3 ± 27.8 mm3 vs. 61 mm3 ± 19 mm3, p = 0.25) (Fig. 4c) further confirming our results of in vivo microscopy.